Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?
Key takeaways
- (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?
- (NASDAQ:REGN) said the FDA and the European Medicines Agency accepted regulatory applications for cemdisiran.
- The company said the FDA granted "Priority Review" for the new drug application and set a target action date in November 2026 after the use of a priority review voucher.
Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds? Fatima Gulzar Mon, June 29, 2026 at 2:58 AM GMT+7 2 min read REGN Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds.
On June 22, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) said the FDA and the European Medicines Agency accepted regulatory applications for cemdisiran. It is to treat adults with "generalized myasthenia gravis" who are anti-acetylcholine receptor antibody-positive.
The company said the FDA granted "Priority Review" for the new drug application and set a target action date in November 2026 after the use of a priority review voucher. The biotech firm also expects a European Commission decision in the second half of 2027. The filings are supported by data from the Phase 3 NIMBLE trial assessing subcutaneous cemdisiran dosed every 12 weeks in adults with symptomatic gMG.